News

COVID-19 worsens CAD symptoms in 71-year-old man: Case report

Infection with SARS-CoV-2, the virus that causes COVID-19, worsened symptoms of cold agglutinin disease (CAD) in a 71-year-old man in whom the autoimmune disease had been stable, a U.S. study reports. This case highlights the need for clinicians to be “mindful of potential preexisting … conditions, particularly [blood-related] diseases,…

Patients on Enjaymo show immune response to COVID-19 vaccines

People with cold agglutinin disease (CAD) who were on Enjaymo (sutimlimab-jome) during clinical trials produced antibodies in response to COVID-19 vaccination, suggesting their ability to mount an immune response was not impaired, a recent study reports. In patients with a waning immune response, a booster dose was enough…

Apellis, Sobi halt development of pegcetacoplan for CAD

Apellis Pharmaceuticals and Swedish Orphan Biovitrum (Sobi) have stopped the clinical development of the experimental therapy pegcetacoplan for cold agglutinin disease (CAD). The decision, which includes discontinuing a Phase 3 clinical trial of the therapy in adults, was based on a realignment of the companies’ priorities in…

Rituximab for CAD does not raise risk of severe COVID-19: Study

Rituximab does not seem to increase the risk for severe outcomes compared with other cold agglutinin disease (CAD) treatments in people who have the disease and COVID-19, according to a review study. “Nonetheless, caution is advised when using rituximab in CAD patients with COVID-19 and underlying [autoimmune] conditions…

Epstein–Barr virus is cause of boy’s complicated secondary CAD

A young boy in Portugal developed cold agglutinin disease (CAD) and an inflammatory condition called hemophagocytic lymphohistiocytosis (HLH) secondary to an infection with the Epstein-Barr virus, which can cause infectious mononucleosis, or mono. The boy recovered fully after being treated with corticosteroids, a type of anti-inflammatory and immunosuppressive medication,…